Patient privacy has become more top of mind as the COVID-19 pandemic continues and a larger part of the population is participating in clinical trials. Read More
Approximately 37.8 percent of more than 350 cancer trials worldwide that were disrupted by COVID-19 have since resumed, according to a report by life sciences analytics firm GlobalData. The report noted that this represents the largest proportion of trials that have resumed since the pandemic began. Read More
Misinformation and mistrust are two of the biggest culprits behind minority groups’ reluctance to participate in COVID-19 trials, but community outreach, education and replacing fake “facts” with real ones are the first steps in easing their fear of clinical research. Read More
Shrinking awareness of and growing distrust for clinical research could make it challenging for trials to recruit and retain study participants in the near term, according to preliminary results from an ongoing study by the Center for Information and Study on Clinical Research Participation (CISCRP). Read More
As concerns mount over the FDA coming under undue pressure to approve a COVID-19 vaccine, FDA Commissioner Stephen Hahn said again yesterday that the agency won’t take any shortcuts. Read More
Three top FDA officials, including Commissioner Stephen Hahn, last week shared with their medical peers the agency’s primary considerations when reviewing COVID-19 vaccine trials, reassuring them that these vaccine candidates would face the same level of scrutiny as all other FDA-approved products. Read More
RSS
